Cellares and Sonoma Biotherapeutics agreed to automate engineered regulatory T cell (Treg) manufacturing for SBT-77-7101, which is in Phase I development for poly-refractory rheumatoid arthritis in patients who exhausted available treatment options. The collaboration focuses on translating SonomaBio’s process to Cellares’ Cell Shuttle platform and automating in-process and release testing through the Cell Q quality control system. The companies framed the work around the technical sensitivity of Tregs, noting that manufacturing consistency can be a central determinant of clinical feasibility. The announcement also highlights Cellares’ infrastructure ambitions, including a commercial-scale smart factory and additional facilities in Europe and Japan. For the field, the partnership reinforces the direction of travel toward automation and standardized quality-by-design in cell therapy, aiming to reduce operational bottlenecks as trials expand.